checkAd

     345  0 Kommentare Mainz Biomed Reports Results of 2024 Annual General Meeting

    BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, held its annual general meeting (“Annual General Meeting”) on Friday, May 31, 2024 in Amsterdam, The Netherlands. Holders of 2,431,947 ordinary shares, representing approximately 10.9% of our outstanding shares on May 3, 2024, the record date for the Annual General Meeting, were present at such meeting, which constituted a quorum under Dutch law. Each of the matters presented at the Annual General Meeting received the requisite shareholder approval as set below:

      Proposal For Against Abstain
     1. Adoption of the statutory annual accounts for the financial year ended 31 December 2023 2,400,449 22,528 8,970
     2. Discharge from liability of the directors for their management and supervision during the financial year ended 31 December 2023 2,187,602 198,949 45,396
     3. Amendment of the articles of association and authorization of CMS to have the deed of amendment of articles of association executed 2,344,801 32,166 54,980
     4. Extension of the authorization of the board to acquire ordinary shares or depositary receipts thereof 2,229,837 169,972 32,138
     5. Extension of the authorization of the board to acquire preferred shares or depositary receipts thereof 2,103,796 296,901 31,250
     6. Reappointment of Mr. G. Baechler as executive director 2,368,376 31,476 32,095
     7. Reappointment of Mr. H.J. Hekland as non-executive director 2,371,381 31,481 29,085
     8. Reappointment of Mr. G.J. Tibbitts as non-executive director 2,378,154 46,443 7,350
     9. Reappointment of Dr. H. Dreismann as non-executive director 2,372,910 29,939 29,098
     10. Assignment of Kreston Lentink Audit B.V. as Dutch auditor and authorization of the board to assign a US auditor at its discretion for the financial year ending 31 December 2024 2,378,052 25,907 27,988

    No other matters were voted upon at the Annual General Meeting.

    Seite 1 von 4



    Diskutieren Sie über die enthaltenen Werte



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Mainz Biomed Reports Results of 2024 Annual General Meeting BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) - Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, held its annual general meeting (“Annual General …

    Schreibe Deinen Kommentar

    Disclaimer